Sanctuary Advisors LLC Buys Shares of 2,663 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sanctuary Advisors LLC bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,663 shares of the medical research company’s stock, valued at approximately $735,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. First Eagle Investment Management LLC lifted its stake in shares of Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after buying an additional 634,311 shares during the period. Swedbank AB acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $1,824,000. DAVENPORT & Co LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $15,340,000. Gabelli Funds LLC lifted its stake in shares of Bio-Rad Laboratories by 16.8% during the first quarter. Gabelli Funds LLC now owns 41,800 shares of the medical research company’s stock worth $14,457,000 after buying an additional 6,000 shares during the period. Finally, Qsemble Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $567,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BIO. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective for the company. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Citigroup raised shares of Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and raised their target price for the stock from $350.00 to $400.00 in a report on Tuesday, October 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $401.00 target price on shares of Bio-Rad Laboratories in a report on Friday, August 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $368.20.

Insider Transactions at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP James Barry sold 623 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Stock Up 1.1 %

BIO opened at $336.92 on Monday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $364.24. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. The company has a fifty day moving average of $328.84 and a two-hundred day moving average of $306.88. The stock has a market capitalization of $9.61 billion, a price-to-earnings ratio of -32.52 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company had revenue of $638.50 million during the quarter, compared to analysts’ expectations of $645.79 million. During the same quarter in the previous year, the company earned $3.00 earnings per share. The firm’s revenue for the quarter was down 6.3% on a year-over-year basis. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.